BML-111 ≥99% Lipoxin A4 agonist
About this item
Lipoxin A₄ analog and potent lipoxin A₄ receptor agonist (IC₅₀ = 70 nM). Antiangiogenic, antitumorigenic and anti-infla mMatory agent. Active in vivo and in vitro.
Caution: All products are FOR RESEARCH USE ONLY. PRODUCTS ARE NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES. Customer is granted a limited use non-exclusive licence for its own internal research. Any control manufacturer supplies with a Product is limited to use only to validate the relevant Product. By using the Product, Customers agree not to attempt to reverse engineer or otherwise perform any compositional, structural, functional or other analyses directed to learning the methodology, formulae, sequences, processes, make-up or production of any of the Products or portions thereof.
- CAS Number:78606-80-1
- Molecular Weight:192,2 g/mol
2 Options Available Below
Product Details & Documents
Lipoxin A₄ analog and potent lipoxin A₄ receptor agonist (IC₅₀ = 70 nM). Antiangiogenic, antitumorigenic and anti-infla mMatory agent. Active in vivo and in vitro.
Caution: All products are FOR RESEARCH USE ONLY. PRODUCTS ARE NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES. Customer is granted a limited use non-exclusive licence for its own internal research. Any control manufacturer supplies with a Product is limited to use only to validate the relevant Product. By using the Product, Customers agree not to attempt to reverse engineer or otherwise perform any compositional, structural, functional or other analyses directed to learning the methodology, formulae, sequences, processes, make-up or production of any of the Products or portions thereof.
- CAS Number:78606-80-1
- Molecular Weight:192,2 g/mol
Specifications for Product Family
Specification Test Results
- Constituents::100% BML-111
Product Family Options
Product Information
Recommendations will be personalized based on your shopping preferences only if you have given your consent by enabling "Enhance my Shopping Experience" on the "Personal Info page".
Otherwise, you will receive generic recommendations.



